| Name | Atoltivimab |
|---|
| Description | Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and Drug Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection[1]. |
|---|---|
| Related Catalog | |
| Target |
Ebolaviru (EBOV)[1] |
| References |
| No Any Chemical & Physical Properties |